checkAd
    Lee's Pharmaceutical Holdings Aktie
    0,1410
     
    EUR
    +2,17 %
    +0,0030 EUR
    Letzter Kurs 03.05.24 Lang & Schwarz
    0,1350
     
    EUR
    3.571 STK
    Geldkurs 03.05.24
    0,1470
     
    EUR
    3.571 STK
    Briefkurs 03.05.24
    ISIN: KYG5438W1116 · WKN: A12CU5 · Kaiman-Inseln

    Lee's Pharmaceutical Holdings Bilanz & GuV

    GuV in Mio EUR

    20192020202120222023e
    Umsatz1.218,911.216,721.266,161.233,151.053,03
    Bruttoergebnis vom Umsatz798,26781,07953,15770,76551,31
    EBITDA315,71284,481.975,09226,98190,65
    EBIT221,57156,981.978,5876,5641,15
    Ergebnis vor Steuer122,89134,041.969,3767,8630,79
    Ergebnis nach Steuern125,55129,321.987,1851,2816,70

    Bilanz in Mio EUR

    20192020202120222023e
    Aktiva3.640,243.252,923.636,902.782,032.890,67
    Umlaufvermögen1.441,281.239,10963,32651,63656,63
    Summe Anlagevermögen2.198,962.013,832.673,582.130,392.234,04
    Passiva3.640,243.252,923.636,902.782,032.890,67
    Summe kurzfristige Verbindlichkeiten908,49944,05922,58650,10648,82
    Summe langfristige Verbindlichkeiten254,31193,49323,16289,40281,25
    Summe Fremdkapital1.162,801.137,541.172,32857,92930,07
    Minderheitenanteil (Fremdanteil)181,54-34,42---
    Bilanzielles Eigenkapital2.295,902.149,802.464,581.924,112.038,96

    Cashflow in EUR

    20192020202120222023e
    Cashflow399,95 Mio.218,91 Mio.210,68 Mio.283,63 Mio.110,08 Mio.

    Dividende

    20192020202120222023e
    Dividende je Aktie0,070,060,040,020,02
    Kennzahlen und Daten von

    Dividendenrechner

    Zum Dividendenrechner

    Dividendentermine der Branche

    DatumUnternehmenTermin
    09.05.2024
    Pfizer
    Dividendentermin
    13.05.2024
    Sanofi
    Dividendentermin
    13.05.2024
    Sanofi
    Dividendentermin
    16.05.2024
    Royalty Pharma Registered (A)
    Dividendentermin
    28.05.2024
    Lee's Pharmaceutical Holdings
    Dividendentermin
    30.05.2024
    Ipsen
    Dividendentermin
    31.05.2024
    CSPC Pharmaceutical Group
    Dividendentermin
    03.06.2024
    Boiron
    Dividendentermin

    Lee's Pharmaceutical Holdings Unternehmensprofil

    Lee's Pharmaceutical Holdings Insidertrades 2024

    Zeitraum 

      Kennzahlen in EUR

      20192020202120222023e2023e2024e2024e
      Dividendenrendite1,50 %1,40 %2,19 %1,33 %1,68 %-
      		1,55 %
      Kurs-Gewinn-Verhältnis (KGV)19,8320,08--
      		-7,25-
      Kurs-Cash-Flow-Verhältnis (KCV)6,1311,94--
      		-
      		-
      Kurs-Buchwert-Verhältnis (KBV)1,071,21--
      		-
      		-
      Kurs-Umsatz-Verhältnis (KUV)2,022,13--
      		-
      		-
      Umsatz je Aktie2,062,07--
      		-
      		-
      Cashflow je Aktie0,680,37--
      		-
      		-
      Umsatzrentabilität10,30 %10,63 %156,95 %4,16 %
      		1,59 %
      		-
      Eigenkapitalrendite5,47 %6,02 %80,63 %2,67 %
      		0,82 %
      		-
      Anlageintensität60,00 %62,00 %74,00 %77,00 %
      		77,00 %
      		-
      Arbeitsintensität40,00 %38,00 %26,00 %23,00 %
      		23,00 %
      		-
      Gesamtrendite3,45 %3,98 %54,64 %1,84 %
      		0,58 %
      		-
      Eigenkapitalquote63,07 %66,09 %67,77 %69,16 %
      		70,54 %
      		-
      Fremdkapitalquote31,94 %34,97 %32,23 %30,84 %
      		32,17 %
      		-
      Verschuldungsgrad50,65 %52,91 %47,57 %44,59 %
      		45,61 %
      		-
      Working Capital in Mio.532,78295,0540,741,53
      		7,81
      		-
      Deckungsgrad A104,41 %106,75 %92,18 %90,32 %
      		91,27 %
      		-
      Deckungsgrad B104,41 %106,75 %95,33 %93,95 %
      		94,43 %
      		-
      Deckungsgrad C93,54 %88,53 %84,82 %84,11 %
      		83,31 %
      		-

      Aktieninformationen in EUR

      20192020
      Aktien im Umlauf in Mio.592,31588,13

      Mitarbeiter

      2024e
      Anzahl Mitarbeiter1.057


      Aktionärsstruktur

      Profil

      Lees Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the Peoples Republic of China. The company focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates through Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells self-developed and generic pharmaceutical products, such as Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat Urea cycle disorders. The Licensed-In Products segment trades in licensed-in pharmaceutical products, including Carnitene for the treatment of carnitine deficiency; Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil to treat oral mucositis pain; Ferplex to treat iron deficiency anemia; and Gaslon N for gastric ulcer and gastritis. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkins disease; Omacor to treat Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Unidrox for urinary and respiratory tract infections; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.

      Kennzahlen und Daten von